Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition

被引:178
作者
Grant, Oliver C. [1 ]
Montgomery, David [1 ]
Ito, Keigo [1 ]
Woods, Robert J. [1 ]
机构
[1] Univ Georgia, Complex Carbohydrate Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA
基金
美国国家卫生研究院;
关键词
RECEPTOR-BINDING DOMAIN; MOLECULAR-DYNAMICS SIMULATIONS; BIOMOLECULAR FORCE-FIELD; MERS-COV; STRUCTURAL DEFINITION; NEUTRALIZATION EPITOPE; GLYCOSYLATION; HEMAGGLUTININ; ANTIBODY; SPECIFICITY;
D O I
10.1038/s41598-020-71748-7
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Here we have generated 3D structures of glycoforms of the spike (S) glycoprotein from SARS-CoV-2, based on reported 3D structures and glycomics data for the protein produced in HEK293 cells. We also analyze structures for glycoforms representing those present in the nascent glycoproteins (prior to enzymatic modifications in the Golgi), as well as those that are commonly observed on antigens present in other viruses. These models were subjected to molecular dynamics (MD) simulation to determine the extent to which glycan microheterogeneity impacts the antigenicity of the S glycoprotein. Lastly, we have identified peptides in the S glycoprotein that are likely to be presented in human leukocyte antigen (HLA) complexes, and discuss the role of S protein glycosylation in potentially modulating the innate and adaptive immune response to the SARS-CoV-2 virus or to a related vaccine. The 3D structures show that the protein surface is extensively shielded from antibody recognition by glycans, with the notable exception of the ACE2 receptor binding domain, and also that the degree of shielding is largely insensitive to the specific glycoform. Despite the relatively modest contribution of the glycans to the total molecular weight of the S trimer (17% for the HEK293 glycoform) they shield approximately 40% of the protein surface.
引用
收藏
页数:11
相关论文
共 89 条
  • [1] Human Influenza A Virus Hemagglutinin Glycan Evolution Follows a Temporal Pattern to a Glycan Limit
    Altman, Meghan O.
    Angel, Matthew
    Kosik, Ivan
    Trovao, Nidia S.
    Zost, Seth J.
    Gibbs, James S.
    Casalino, Lorenzo
    Amaro, Rommie E.
    Hensley, Scott E.
    Nelson, Martha I.
    Yewdell, Jonathan W.
    [J]. MBIO, 2019, 10 (02):
  • [2] Amaro RE, 2012, METHODS MOL BIOL, V819, P575, DOI 10.1007/978-1-61779-465-0_34
  • [3] N-Glycosylation of Seasonal Influenza Vaccine Hemagglutinins: Implication for Potency Testing and Immune Processing
    An, Yanming
    Parsons, Lisa M.
    Jankowska, Ewa
    Melnyk, Darya
    Joshi, Manju
    Cipollo, John F.
    [J]. JOURNAL OF VIROLOGY, 2019, 93 (02)
  • [4] Comparative Glycomics Analysis of Influenza Hemagglutinin (H5N1) Produced in Vaccine Relevant Cell Platforms
    An, Yanming
    Rininger, Joseph A.
    Jarvis, Donald L.
    Jing, Xianghong
    Ye, Zhiping
    Aumiller, Jared J.
    Eichelberger, Maryna
    Cipollo, John F.
    [J]. JOURNAL OF PROTEOME RESEARCH, 2013, 12 (08) : 3707 - 3720
  • [5] [Anonymous], 2020, COR DIS 2019 COVID 1
  • [6] A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design
    Avci, Fikri Y.
    Li, Xiangming
    Tsuji, Moriya
    Kasper, Dennis L.
    [J]. NATURE MEDICINE, 2011, 17 (12) : 1602 - U115
  • [7] The direct and indirect effects of glycans on immune function
    Baum, Linda G.
    Cobb, Brian A.
    [J]. GLYCOBIOLOGY, 2017, 27 (07) : 619 - 624
  • [8] The Glycan Shield of HIV Is Predominantly Oligomannose Independently of Production System or Viral Clade
    Bonomelli, Camille
    Doores, Katie J.
    Dunlop, D. Cameron
    Thaney, Victoria
    Dwek, Raymond A.
    Burton, Dennis R.
    Crispin, Max
    Scanlan, Christopher N.
    [J]. PLOS ONE, 2011, 6 (08):
  • [9] A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals
    Casadevall, Arturo
    Joyner, Michael J.
    Pirofski, Liise-Anne
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (05): : 455 - 457
  • [10] The convalescent sera option for containing COVID-19
    Casadevall, Arturo
    Pirofski, Liise-Anne
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (04) : 1545 - 1548